Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831887 | 0.85 | NR4A2 (0.39) | ADORA2ANR4A2CYP2C9EGLN1 | |
| SCHEMBL1733186 | 0.83 | ADORA2A (0.51) | ADORA2ANR4A2CYP2C9EGLN1DNMT1 | |
| SCHEMBL1733878 | 0.82 | NR4A2 (0.45) | NR4A2CYP2C9EGLN1 | |
| SCHEMBL2829516 | 0.82 | NR4A2 (0.50) | NR4A2CYP2C9EGLN1 | |
| SCHEMBL1733561 | 0.82 | NR4A2 (0.58) | ADORA2ANR4A2CYP2C9EGLN1 | |
| SCHEMBL3766980 | 0.81 | CYP2C9 (0.64) | ADORA2ANR4A2CYP2C9EGLN1DNMT1 | |
| SCHEMBL1734156 | 0.81 | NR4A2 (0.66) | ADORA2ANR4A2CYP2C9EGLN1DNMT1 | |
| SCHEMBL1733803 | 0.81 | EGLN1 (0.42) | NR4A2CYP2C9EGLN1 | |
| SCHEMBL1734186 | 0.79 | NR4A2 (0.70) | NR4A2CYP2C9EGLN1 | |
| SCHEMBL3772491 | 0.79 | ADORA2A (0.51) | ADORA2ANR4A2CYP2C9EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225243-B1 | Derivatives of N-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-11-16 | — | — | EP | claimed |
| US-20100317686-A1 | N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| EP-2225243-A2 | DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZOÝL,2- A¨PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-09-08 | — | — | EP | claimed |
| WO-2009106751-A2 | DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[L,2- A]PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-03 | — | — | WO | claimed |
| EP-2225243-B1 | Derivatives of N-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-20100317686-A1 | N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317686-A1 | N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | IDH1, IDH2, XDH | ADORA2A 200/4885NR4A2 1619/4885CYP2C9 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.